CBP-1019
- Generic Name
- CBP-1019
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
Phase 1
Recruiting
- Conditions
- Solid Tumor
- Interventions
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 128
- Registration Number
- NCT06576037
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Cancer, BreastCancer, LungCancer of PancreasCancer ColorectalCancer of Esophagus
- Interventions
- First Posted Date
- 2023-04-26
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Coherent Biopharma (Hefei) Co., Ltd.
- Target Recruit Count
- 260
- Registration Number
- NCT05830097
- Locations
- 🇺🇸
TOI Clinical Research LLC, Cerritos, California, United States
🇺🇸Next Oncology, Fairfax, Virginia, United States
🇺🇸Northwell Health Inc., Manhasset, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath